as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,670.6
Change
+16.1 (0.97%)
Open
₹1,650.0
Prev. Close
₹1,654.5
Day High
₹1,675.0
Day Low
₹1,647.0
Volume Analysis
Traded
36,339
Delivered
20,252
Delivery %
55.73%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Promoter holding is rising
- •Strong operating margin (23.0%)
Weaknesses (1)
- •Low return on equity (9.8%)
Opportunities (2)
- •Strong 3-year EPS growth (19.4%)
- •Strong 3-year revenue growth (18.9%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,709.4 | ₹1,692.2 | ₹1,681.4 | ₹1,664.2 | ₹1,653.4 | ₹1,636.2 | ₹1,625.4 |
| Fibonacci | ₹1,692.2 | ₹1,681.5 | ₹1,674.9 | ₹1,664.2 | ₹1,653.5 | ₹1,646.9 | ₹1,636.2 |
| Camarilla | ₹1,678.3 | ₹1,675.73 | ₹1,673.17 | ₹1,664.2 | ₹1,668.03 | ₹1,665.47 | ₹1,662.9 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-4.13%
1 Week
-1.33%
1 Month
+13.64%
3 Months
-2.84%
6 Months
+4.53%
1 Year
-11.1%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹479.84
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.46%
Net margin 14.81% × asset turnover 0.45x × equity multiplier 1.27x
Company Overview
Sector
Healthcare
Market Cap
₹17,041 Cr
P/E (TTM)
53.9
ROE
9.8%
Book Value
₹322.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Poly Medicure Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 63/100. The strongest factor is Financial Strength (100/100), while Valuation (18/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (23.0%); low return on equity (9.8%). FII holding has been falling.
TopFund Score — Fundamentals Quality
63/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Company has a low return on equity of 13.3% over last 3 years.
- −Debtor days have increased from 83.9 to 103 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Poly Medicure to participate in Avendus Spark INDX annual investor conference on 18 November in Mumbai.
QIP monitoring report for quarter ended Sep 30, 2026; Rs98,534.37 lakh proceeds, Rs9,544.62 lakh capex used; project delayed.
Audio recording of 05 Nov 2026 earnings call for Q2 FY27 available on company website.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 337 | 340 | 378 | 385 | 420 | 424 | 441 | 403 | 444 | 494 | 535 | 525 | 581 |
| Expenses + | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 | 382 | 424 | 400 | 443 |
| Operating Profit | 84 | 90 | 96 | 104 | 115 | 114 | 119 | 106 | 115 | 111 | 110 | 125 | 138 |
| OPM % | 25.0% | 27.0% | 26.0% | 27.0% | 27.0% | 27.0% | 27.0% | 26.0% | 26.0% | 23.0% | 21.0% | 24.0% | 24.0% |
| Other Income + | 15 | 17 | 15 | 17 | 27 | 24 | 27 | 43 | 35 | 21 | 19 | 35 | 30 |
| Interest | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 6 | 6 | 6 | 7 |
| Depreciation | 16 | 16 | 16 | 20 | 21 | 21 | 21 | 23 | 25 | 29 | 38 | 36 | 35 |
| Profit before tax | 81 | 88 | 92 | 98 | 118 | 113 | 123 | 123 | 122 | 98 | 85 | 117 | 125 |
| Tax % | 23.0% | 26.0% | 26.0% | 25.0% | 26.0% | 25.0% | 25.0% | 24.0% | 25.0% | 27.0% | 24.0% | 27.0% | 24.0% |
| Net Profit + | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 | 71 | 65 | 85 | 95 |
| EPS in Rs | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 9 | 7 | 7 | 8 | 9 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 23 | 19 | 23 | 20 | 25 | 25 | 17 | 5 | 6 | 16 | 21 | 30 | 31 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,669 | 1,875 | 2,134 |
| Expenses + | 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,014 | 1,213 | 1,429 | 1,650 |
| Operating Profit | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 361 | 456 | 446 | 484 |
| OPM % | 22.0% | 21.0% | 21.0% | 23.0% | 22.0% | 24.0% | 28.0% | 23.0% | 24.0% | 26.0% | 27.0% | 24.0% | 23.0% |
| Other Income + | 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 94 | 119 | 106 |
| Interest | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 14 | 21 | 26 |
| Depreciation | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 63 | 83 | 116 | 138 |
| Profit before tax | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 453 | 427 | 426 |
| Tax % | 27.0% | 27.0% | 27.0% | 27.0% | 35.0% | 24.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | — |
| Net Profit + | 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 321 | 316 |
| EPS in Rs | 7 | 5 | 6 | 8 | 7 | 11 | 14 | 15 | 19 | 27 | 33 | 32 | 31 |
| Dividend Payout % | 18.0% | 27.0% | 40.0% | 25.0% | 27.0% | 18.0% | 18.0% | 16.0% | 16.0% | 11.0% | 10.0% | 11.0% | — |
| Sales growth | 21 | 6 | 10 | 14 | 18 | 13 | 14 | 17 | 21 | 23 | 21 | 12 | 25 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 | 3,055 | 3,215 |
| Borrowings + | 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 180 | 354 | 412 |
| Other Liabilities + | 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 215 | 246 | 401 | 478 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,861 | 4,155 |
| Fixed Assets + | 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | 1,694 | 1,861 |
| CWIP | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 | 99 | 110 |
| Investments | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,076 | 755 | 746 |
| Other Assets + | 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 748 | 930 | 1,313 | 1,438 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,861 | 4,155 |
| Equity Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 | 51 | 51 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 63 | 63 | 56 | 75 | 106 | 131 | 119 | 123 | 191 | 266 | 233 | 246 |
| Cash from Investing Activity + | -59 | -31 | -56 | -88 | -101 | -109 | -436 | -85 | -179 | -241 | -1,187 | -224 |
| Cash from Financing Activity + | -6 | -31 | 0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 | 20 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 | 43 |
| Free Cash Flow | 13 | 31 | 0 | -7 | 31 | 25 | 24 | -31 | -48 | -9 | -97 | -59 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 101 | 88 | 79 | 80 | 102 | 100 | 75 | 80 | 93 | 94 | 71 | 78 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 27.28% | 27.25% | 14.72% | 13.23% | 13.57% | 14.13% | 14.43% | 14.28% | 14.34% | 16.08% | 15.94% | 16.33% |
| Promoters | 53.17% | 53.14% | 66.02% | 62.56% | 62.44% | 62.44% | 62.44% | 62.42% | 62.42% | 62.42% | 62.42% | 62.41% |
| FII | 14.1% | 12.37% | 9.91% | 11.88% | 12.33% | 11.46% | 11.41% | 9.77% | 9.41% | 5.92% | 5.56% | 5.36% |
| DII | 5.46% | 7.21% | 9.34% | 12.33% | 11.66% | 11.96% | 11.72% | 13.53% | 13.84% | 15.6% | 16.08% | 15.9% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Poly Medicure Limited (this stock) | 17,041 | 53.9 | 5.22 | 9.8% |
| Molbio Diagnostics Ltd | 17,111 | 236.0 | 11.89 | 15.6% |
| Dr Agarwals Health Care L | 17,460 | 97.5 | 7.8 | 6.41% |
| Cohance Lifesciences Ltd | 17,511 | 359.0 | 4.49 | 4.89% |
| Pfizer Ltd | 17,601 | 115.0 | 12.74 | 19.8% |
| Shilpa Medicare Ltd | 17,616 | 55.1 | 6.39 | 9.3% |
| Alivus Life Sciences Ltd | 17,803 | 50.6 | — | — |
Which Mutual Funds Hold Poly Medicure Limited?
Frequently Asked Questions about Poly Medicure Limited
Poly Medicure Limited (POLYMED) closed at ₹1,670.6 on NSE on 19 November 2026, up 16.1 (0.97%) from the previous close.
Poly Medicure Limited trades on the NSE (National Stock Exchange of India) under the symbol POLYMED.
Poly Medicure Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 53.9.
Poly Medicure Limited has a dividend yield of 0.21%.
Poly Medicure Limited's 52-week high is ₹2,024.0 and its 52-week low is ₹1,182.0.
Poly Medicure Limited has a market capitalisation of ₹17,041 crore.
Poly Medicure Limited has a TopFund Quality Score of 63/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Poly Medicure Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.